rabbit anti-human cd4 antibody 104r-15 Search Results


mouse monoclonal anti vegfr2  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology mouse monoclonal anti vegfr2
Mouse Monoclonal Anti Vegfr2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti-human+cd4+antibody+104r-15/VEGFR2/pm41197764-144-222-226
Average 96 stars, based on 1 article reviews
mouse monoclonal anti vegfr2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
anti pd l1 rabbit igg e1l3n  (Cell Signaling Technology Inc)
98
Cell Signaling Technology Inc anti pd l1 rabbit igg e1l3n
Anti Pd L1 Rabbit Igg E1l3n, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti-human+cd4+antibody+104r-15/PD-L1+XP+Rabbit+mAb/pmc04841565-84-40-47
Average 98 stars, based on 1 article reviews
anti pd l1 rabbit igg e1l3n - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
anti phosphorylated h2ax  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc anti phosphorylated h2ax
Homologous recombination repair pathway (A) Oncoprint of HRR pathway components showing frequent LOH events in cohort 1. (B) Boxplot of genomic alteration counts in the HRR pathway per sample shows high occurrence in P2/P3, but not statistically significant. (C) The HRD score is higher in P2/P3 compared to P1. (D) The HRD score positively correlates with CIN. (E) The RAD51 IHC scores are lower in P2/P3 compared to P1, which is concordant with the HRD scores of these subtypes. (F) Boxplot of HRD score comparison between paired primary and metastatic samples of P2 and P3. Metastatic samples of P3 show a significant increase. Although overall not statistically significant, 3 out of 4 samples of P2 show HRD score increases. (G) UpSet plot of thetop 5 altered genes. BRCA2 is the top altered gene with multiple different cooccurrence partners. (H) Boxplot of HRD scores between BRCA2 LOH and non-LOH groups showing significant increase of HRD scores in the LOH group. (I) Boxplots of mRNA and protein expression between LOH and non-LOH groups for each HRR gene. Among 37 HRR genes ( FANCD2 was excluded due to low LOH event number), 16 proteins were quantified in cohort 1 and are shown here. (J) Bar plot showing frequencies of BRCA2-retaining samples in each subtype. P2/P3 subtypes, especially P2, show decrease of BRCA2 retention compared to P1. (K) The RAD50 IHC score does not change significantly between HRD-low and HRD-high groups, but it shows a downward trend in P2/P3 compared to P1. (L) Boxplot of phosphorylated <t>H2AX</t> IHC scores by subtypes. (M) Boxplot of XRCC5/6 protein expression by subtypes. P3 shows significantly higher expression of XRCC5/6 compared to P1 or P2. (N) Boxplot of PARP1 protein expression between HRD-low and HRD-high groups by subtypes. (O) Kaplan-Meier analysis of overall and recurrence-free survival in combined cohorts 1 and 2, stratified by median values of RAD51 H-score and BRCA2 tumor cell positivity.
Anti Phosphorylated H2ax, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti-human+cd4+antibody+104r-15/Phospho-Histone+H2A%2EX+(Ser139)+Rabbit+mAb/bio_rxiv__2025__11__19__689365-370-103-105
Average 99 stars, based on 1 article reviews
anti phosphorylated h2ax - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
anti cdk2  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anti cdk2
Homologous recombination repair pathway (A) Oncoprint of HRR pathway components showing frequent LOH events in cohort 1. (B) Boxplot of genomic alteration counts in the HRR pathway per sample shows high occurrence in P2/P3, but not statistically significant. (C) The HRD score is higher in P2/P3 compared to P1. (D) The HRD score positively correlates with CIN. (E) The RAD51 IHC scores are lower in P2/P3 compared to P1, which is concordant with the HRD scores of these subtypes. (F) Boxplot of HRD score comparison between paired primary and metastatic samples of P2 and P3. Metastatic samples of P3 show a significant increase. Although overall not statistically significant, 3 out of 4 samples of P2 show HRD score increases. (G) UpSet plot of thetop 5 altered genes. BRCA2 is the top altered gene with multiple different cooccurrence partners. (H) Boxplot of HRD scores between BRCA2 LOH and non-LOH groups showing significant increase of HRD scores in the LOH group. (I) Boxplots of mRNA and protein expression between LOH and non-LOH groups for each HRR gene. Among 37 HRR genes ( FANCD2 was excluded due to low LOH event number), 16 proteins were quantified in cohort 1 and are shown here. (J) Bar plot showing frequencies of BRCA2-retaining samples in each subtype. P2/P3 subtypes, especially P2, show decrease of BRCA2 retention compared to P1. (K) The RAD50 IHC score does not change significantly between HRD-low and HRD-high groups, but it shows a downward trend in P2/P3 compared to P1. (L) Boxplot of phosphorylated <t>H2AX</t> IHC scores by subtypes. (M) Boxplot of XRCC5/6 protein expression by subtypes. P3 shows significantly higher expression of XRCC5/6 compared to P1 or P2. (N) Boxplot of PARP1 protein expression between HRD-low and HRD-high groups by subtypes. (O) Kaplan-Meier analysis of overall and recurrence-free survival in combined cohorts 1 and 2, stratified by median values of RAD51 H-score and BRCA2 tumor cell positivity.
Anti Cdk2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti-human+cd4+antibody+104r-15/CDK2+XP+Rabbit+mAb/bio_rxiv__2025__11__19__689365-370-63-64
Average 96 stars, based on 1 article reviews
anti cdk2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
anti aurka  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc anti aurka
Homologous recombination repair pathway (A) Oncoprint of HRR pathway components showing frequent LOH events in cohort 1. (B) Boxplot of genomic alteration counts in the HRR pathway per sample shows high occurrence in P2/P3, but not statistically significant. (C) The HRD score is higher in P2/P3 compared to P1. (D) The HRD score positively correlates with CIN. (E) The RAD51 IHC scores are lower in P2/P3 compared to P1, which is concordant with the HRD scores of these subtypes. (F) Boxplot of HRD score comparison between paired primary and metastatic samples of P2 and P3. Metastatic samples of P3 show a significant increase. Although overall not statistically significant, 3 out of 4 samples of P2 show HRD score increases. (G) UpSet plot of thetop 5 altered genes. BRCA2 is the top altered gene with multiple different cooccurrence partners. (H) Boxplot of HRD scores between BRCA2 LOH and non-LOH groups showing significant increase of HRD scores in the LOH group. (I) Boxplots of mRNA and protein expression between LOH and non-LOH groups for each HRR gene. Among 37 HRR genes ( FANCD2 was excluded due to low LOH event number), 16 proteins were quantified in cohort 1 and are shown here. (J) Bar plot showing frequencies of BRCA2-retaining samples in each subtype. P2/P3 subtypes, especially P2, show decrease of BRCA2 retention compared to P1. (K) The RAD50 IHC score does not change significantly between HRD-low and HRD-high groups, but it shows a downward trend in P2/P3 compared to P1. (L) Boxplot of phosphorylated <t>H2AX</t> IHC scores by subtypes. (M) Boxplot of XRCC5/6 protein expression by subtypes. P3 shows significantly higher expression of XRCC5/6 compared to P1 or P2. (N) Boxplot of PARP1 protein expression between HRD-low and HRD-high groups by subtypes. (O) Kaplan-Meier analysis of overall and recurrence-free survival in combined cohorts 1 and 2, stratified by median values of RAD51 H-score and BRCA2 tumor cell positivity.
Anti Aurka, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti-human+cd4+antibody+104r-15/Aurora+A+XP+Rabbit+mAb/bio_rxiv__2025__11__19__689365-370-46-47
Average 93 stars, based on 1 article reviews
anti aurka - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Homologous recombination repair pathway (A) Oncoprint of HRR pathway components showing frequent LOH events in cohort 1. (B) Boxplot of genomic alteration counts in the HRR pathway per sample shows high occurrence in P2/P3, but not statistically significant. (C) The HRD score is higher in P2/P3 compared to P1. (D) The HRD score positively correlates with CIN. (E) The RAD51 IHC scores are lower in P2/P3 compared to P1, which is concordant with the HRD scores of these subtypes. (F) Boxplot of HRD score comparison between paired primary and metastatic samples of P2 and P3. Metastatic samples of P3 show a significant increase. Although overall not statistically significant, 3 out of 4 samples of P2 show HRD score increases. (G) UpSet plot of thetop 5 altered genes. BRCA2 is the top altered gene with multiple different cooccurrence partners. (H) Boxplot of HRD scores between BRCA2 LOH and non-LOH groups showing significant increase of HRD scores in the LOH group. (I) Boxplots of mRNA and protein expression between LOH and non-LOH groups for each HRR gene. Among 37 HRR genes ( FANCD2 was excluded due to low LOH event number), 16 proteins were quantified in cohort 1 and are shown here. (J) Bar plot showing frequencies of BRCA2-retaining samples in each subtype. P2/P3 subtypes, especially P2, show decrease of BRCA2 retention compared to P1. (K) The RAD50 IHC score does not change significantly between HRD-low and HRD-high groups, but it shows a downward trend in P2/P3 compared to P1. (L) Boxplot of phosphorylated H2AX IHC scores by subtypes. (M) Boxplot of XRCC5/6 protein expression by subtypes. P3 shows significantly higher expression of XRCC5/6 compared to P1 or P2. (N) Boxplot of PARP1 protein expression between HRD-low and HRD-high groups by subtypes. (O) Kaplan-Meier analysis of overall and recurrence-free survival in combined cohorts 1 and 2, stratified by median values of RAD51 H-score and BRCA2 tumor cell positivity.

Journal: bioRxiv

Article Title: Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilities

doi: 10.1101/2025.11.19.689365

Figure Lengend Snippet: Homologous recombination repair pathway (A) Oncoprint of HRR pathway components showing frequent LOH events in cohort 1. (B) Boxplot of genomic alteration counts in the HRR pathway per sample shows high occurrence in P2/P3, but not statistically significant. (C) The HRD score is higher in P2/P3 compared to P1. (D) The HRD score positively correlates with CIN. (E) The RAD51 IHC scores are lower in P2/P3 compared to P1, which is concordant with the HRD scores of these subtypes. (F) Boxplot of HRD score comparison between paired primary and metastatic samples of P2 and P3. Metastatic samples of P3 show a significant increase. Although overall not statistically significant, 3 out of 4 samples of P2 show HRD score increases. (G) UpSet plot of thetop 5 altered genes. BRCA2 is the top altered gene with multiple different cooccurrence partners. (H) Boxplot of HRD scores between BRCA2 LOH and non-LOH groups showing significant increase of HRD scores in the LOH group. (I) Boxplots of mRNA and protein expression between LOH and non-LOH groups for each HRR gene. Among 37 HRR genes ( FANCD2 was excluded due to low LOH event number), 16 proteins were quantified in cohort 1 and are shown here. (J) Bar plot showing frequencies of BRCA2-retaining samples in each subtype. P2/P3 subtypes, especially P2, show decrease of BRCA2 retention compared to P1. (K) The RAD50 IHC score does not change significantly between HRD-low and HRD-high groups, but it shows a downward trend in P2/P3 compared to P1. (L) Boxplot of phosphorylated H2AX IHC scores by subtypes. (M) Boxplot of XRCC5/6 protein expression by subtypes. P3 shows significantly higher expression of XRCC5/6 compared to P1 or P2. (N) Boxplot of PARP1 protein expression between HRD-low and HRD-high groups by subtypes. (O) Kaplan-Meier analysis of overall and recurrence-free survival in combined cohorts 1 and 2, stratified by median values of RAD51 H-score and BRCA2 tumor cell positivity.

Article Snippet: The antibodies used were anti-CD3 (Leica Microsystems, NCL-L-CD3-565, 1/200 dilution), anti-CD4 (Sigma, 104R-15, 1/100 dilution), anti-CD8 (Dako, M7103, 1/1500 dilution), anti-CD68 (Dako, M0876, 1/200 dilution), anti-CD163 (Leica Microsystems, NCL-CD163, 1/250 dilution), anti-MITF (Abcam, ab303530, 1/100 dilution), anti-MYC (Abcam, ab32072, 1/200 dilution), anti-PAX6 (Abcam, ab195045, 1/100 dilution), anti-AURKA (Cell Signaling Technology, #91590, 1/100 dilution), anti-AURKB (Abcam, ab45145, 1/100 dilution), anti-CDK1 (Abcam, ab133327, 1/250 dilution), anti-CDK2 (Cell Signaling Technology, #18048, 1/200 dilution), anti-active YAP1 (Abcam, ab205270, 1/20,000, dilution), anti-TEAD (Abcam, ab97460, 1/400 dilution), anti-NCOR1 (Invitrogen, PA1-844A, 1/1000 dilution), anti-RAD51 (Abcam, ab133534, 1/100 dilution), anti-BRCA2 (Sigma, HPA026815, 1/50 dilution), anti-RAD50 (Cell Signaling Technology, #61915, 1/4000 dilution), anti-phosphorylated H2AX (Cell Signaling Technology, #9718, 1/200 dilution), anti-Ki67 (Biocare, PRM325, 1/100 dilution), anti-IRF1 (Abcam, ab243895, 1/100 dilution), anti-LGALS9 (Abcam, ab227046, 1/200 dilution).

Techniques: Homologous Recombination, Comparison, Expressing